SELECT PUBLICATIONS

Bukowski RM et al. Bevacizumab with or without erlotinib in metastatic renal cell carcinoma
(RCC). Proc ASCO 2006;Abstract 4523.

Escudier B et al. A randomized, controlled, double-blind phase III study (AVOREN)
of bevacizumab/interferon-2a vs placebo/interferon-2a as first-line therapy in
metastatic renal cell carcinoma. Proc ASCO 2007;Abstract 3.

Escudier B et al; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34. Abstract

Escudier B et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib
(BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc ASCO 2005;Abstract 4510.

Motzer RJ et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
N Engl J Med 2007;356(2):115-24. Abstract

Rini BI et al. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-
alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody
(bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004;10(8):2584-6. Abstract

Yang JC et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth
factor antibody, for metastatic renal cell cancer. N Engl J Med 2003;349(5):427-34. Abstract.

Yang JC et al. A randomized double-blind placebo-controlled trial of bevacizumab
(anti-VEGF antibody) demonstrating a prolongation in time to progression in patients
with metastatic renal cancer. Proc ASCO 2002;Abstract 15.

 

 

 

 

 

 

 

 

Home

Editor
Neil Love, MD

Interviews

David I Quinn, MBBS, PhD
- Select publications

Walter Stadler, MD
- Select publications

Mario Lacouture, MD
- Select publications

Bernard J Escudier, MD
- Select publications

CME Information

Faculty Disclosures

Editor's Office